The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an ...
Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
CAR-T translational research demands precise, reproducible, and scalable flow cytometry workflows. Manual centrifugation and antibody preparation steps remain major sources of variability and cell ...
This article is based on a poster originally authored by Weiping Sun, Xing Zhang, Zhaolu Yan, Chen Yu, Spencer Chiang, and Tianfu Zhang. Immunotherapy is an advanced and widely used treatment due to ...
This research investigates how to optimize mRNA transfection in human T-cells utilizing the jetMESSENGER ® transfection reagent. By using advanced bioanalytical instruments like the Incucyte ® ...
To schedule time for flow analysis, call 977-8877. Leave a message if you are unable to reach us immediately and we will return your call as soon as possible. Users are also welcome to stop by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback